FDA Rx-To-OTC Switch Petition Refusal Would Not Result In WellPoint Suit
This article was originally published in The Tan Sheet
Executive Summary
WellPoint Health Networks will not sue FDA if the agency chooses to reject the health insurer's petitions on forcing Rx low- and non-sedating antihistamines to over-the-counter status
You may also be interested in...
FDA’s Crawford Backs Away From Forced Antihistamine Switch Controversy
FDA says it would like to "stimulate" Rx-to-OTC switches where appropriate, but not "force" the policy on drug makers
FDA’s Crawford Backs Away From Forced Antihistamine Switch Controversy
FDA says it would like to "stimulate" Rx-to-OTC switches where appropriate, but not "force" the policy on drug makers
FDA’s Crawford Backs Away From Forced Antihistamine Switch Controversy
FDA says it would like to "stimulate" Rx-to-OTC switches where appropriate, but not "force" the policy on drug makers